Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ? 10 ng/mL
PSA (prostate specific antigen) has not demonstrated sufficient sensitivity and specificity to be useful in the evaluation of prostate carcinoma. To enhance the accuracy of serum PSA the Authors have used a quotient of serum PSA (ng/ml) and prostate volume (calculated by transrectal ultrasound) which is named PSAD (prostate specific antigen density).
Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ? 10 ng/mL